Schizophrenia and "unmet needs": From diagnosis to care in Italy.
Delphi consensus
early diagnosis
schizophrenia
treatment gaps
Journal
European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820
Informations de publication
Date de publication:
13 03 2020
13 03 2020
Historique:
entrez:
14
3
2020
pubmed:
14
3
2020
medline:
12
1
2021
Statut:
epublish
Résumé
Schizophrenia is a leading cause of disability. People living with schizophrenia (PLWS) present unemployment, social isolation, excess mortality and morbidity, and poor quality of life. Early recognition and appropriate treatment reduce the risk of chronicity and comorbidity. Personalization and integration of pharmacological and psychosocial interventions, as well as accurate identification and management of psychiatric and somatic comorbidities, can significantly improve mental and physical health of PLWS, promoting recovery. A three-step Delphi approach was used to explore consensus on the essential components of early recognition and intervention, personalization, and integration of care to improve schizophrenia outcome, and on barriers and challenges to close treatment gaps. The consensus involved 8 Italian experts of schizophrenia, 100 psychiatrists from academic and nonacademic settings, including representatives of Italian Society of Psychiatry, and 65 trainees in psychiatry. A strong consensus (from mostly agree to totally agree) emerged on the importance of early diagnosis (97%), standardized assessments (91%), correct management of somatic and psychiatric comorbidities (99%), and personalization and integration of care (94%). Lack of time, human resources, and training were identified as the main barriers and challenges to the translation of knowledge into clinical practice. The results of this Delphi study demonstrated a strong consensus on main components of schizophrenia care, as well as on unmet needs to promote best practice and gaps between knowledge and clinical practice. The involvement of a large group of professionals and trainees in this in-depth consensus process might contribute to raise awareness and stimulate innovative strategies to improve the outcome of PLWS.
Sections du résumé
BACKGROUND
Schizophrenia is a leading cause of disability. People living with schizophrenia (PLWS) present unemployment, social isolation, excess mortality and morbidity, and poor quality of life. Early recognition and appropriate treatment reduce the risk of chronicity and comorbidity. Personalization and integration of pharmacological and psychosocial interventions, as well as accurate identification and management of psychiatric and somatic comorbidities, can significantly improve mental and physical health of PLWS, promoting recovery.
METHODS
A three-step Delphi approach was used to explore consensus on the essential components of early recognition and intervention, personalization, and integration of care to improve schizophrenia outcome, and on barriers and challenges to close treatment gaps. The consensus involved 8 Italian experts of schizophrenia, 100 psychiatrists from academic and nonacademic settings, including representatives of Italian Society of Psychiatry, and 65 trainees in psychiatry.
RESULTS
A strong consensus (from mostly agree to totally agree) emerged on the importance of early diagnosis (97%), standardized assessments (91%), correct management of somatic and psychiatric comorbidities (99%), and personalization and integration of care (94%). Lack of time, human resources, and training were identified as the main barriers and challenges to the translation of knowledge into clinical practice.
CONCLUSIONS
The results of this Delphi study demonstrated a strong consensus on main components of schizophrenia care, as well as on unmet needs to promote best practice and gaps between knowledge and clinical practice. The involvement of a large group of professionals and trainees in this in-depth consensus process might contribute to raise awareness and stimulate innovative strategies to improve the outcome of PLWS.
Identifiants
pubmed: 32167448
doi: 10.1192/j.eurpsy.2019.8
pii: S0924933819000087
pmc: PMC7315886
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26Références
Schizophr Bull. 2014 Jul;40(4):744-55
pubmed: 23770934
Lancet. 2008 Mar 29;371(9618):1085-97
pubmed: 18374841
Schizophr Res. 2016 Aug;175(1-3):85-89
pubmed: 27094716
J Psychiatr Res. 2018 Aug;103:38-45
pubmed: 29772485
Nat Rev Drug Discov. 2016 Jul;15(7):485-515
pubmed: 26939910
Acta Psychiatr Scand. 2015 May;131(5):387-96
pubmed: 25495118
World Psychiatry. 2014 Oct;13(3):275-87
pubmed: 25273301
J Clin Psychiatry. 2008 Aug;69(8):1299-306
pubmed: 18642975
J Clin Psychiatry. 2007 Jun;68(6):899-907
pubmed: 17592915
Schizophr Res. 2013 Jun;147(1):157-162
pubmed: 23608244
J Psychopharmacol. 2015 Apr;29(4):353-62
pubmed: 25516373
Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
pubmed: 17909124
Schizophr Res. 2004 Dec 15;72(1):41-51
pubmed: 15531406
J Clin Psychiatry. 2013 Feb;74(2):170-9
pubmed: 23473350
JAMA Psychiatry. 2018 Apr 1;75(4):396-404
pubmed: 29450447
Aust N Z J Psychiatry. 2008 Jun;42(6):496-504
pubmed: 18465376
Schizophr Bull. 2014 Apr;40 Suppl 3:S165-94
pubmed: 24778411
J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8
pubmed: 19686636
World Psychiatry. 2012 Jun;11(2):73-9
pubmed: 22654932
Ann Gen Psychiatry. 2017 Feb 10;16:9
pubmed: 28203265
Psychol Med. 2018 Jun;48(8):1359-1366
pubmed: 29017620
Schizophr Bull. 2016 Mar;42(2):327-34
pubmed: 26420905
Eur Neuropsychopharmacol. 2013 Mar;23(3):196-204
pubmed: 22647933
J Clin Psychiatry. 2008;69 Suppl 1:4-17
pubmed: 18484804
Eur Psychiatry. 2015 Mar;30(3):388-404
pubmed: 25749390
Schizophr Res. 2016 Aug;175(1-3):154-160
pubmed: 27209527
Lancet Psychiatry. 2018 Aug;5(8):664-677
pubmed: 29602739
J Psychosoc Nurs Ment Health Serv. 2010 Sep;48(9):44-9
pubmed: 20795590
Schizophr Res. 2014 Oct;159(1):144-50
pubmed: 25182540
Lancet Psychiatry. 2015 Aug;2(8):726-742
pubmed: 26249304
Schizophr Bull. 2006 Apr;32(2):214-9
pubmed: 16481659
Br J Psychiatry. 2011 Aug;199(2):99-105
pubmed: 21804146
Schizophr Res. 2009 Dec;115(2-3):104-14
pubmed: 19822407
Psychol Med. 2017 Sep 4;:1-9
pubmed: 28866985
Schizophr Bull. 2009 Mar;35(2):300-6
pubmed: 19126634
World Psychiatry. 2010 Oct;9(3):169-76
pubmed: 20975864
Schizophr Res. 2016 Oct;176(2-3):431-440
pubmed: 27261419
Am J Psychiatry. 2011 May;168(5):472-85
pubmed: 21406461
Ann Gen Psychiatry. 2012 Aug 02;11(1):21
pubmed: 22856624
CNS Drugs. 2009 Aug;23(8):649-59
pubmed: 19594194
J Psychopharmacol. 2016 Aug;30(8):717-48
pubmed: 27147592
Can J Psychiatry. 2017 Sep;62(9):624-634
pubmed: 28886671
Eur Neuropsychopharmacol. 2013 Dec;23(12):1754-62
pubmed: 24091164